Clinical and economic implications of the use of nanoparticle paclitaxel (Nanoxel) in India

Annals of Oncology

Volumn 24, Issue SUPPLEMENT5, 2013, Pages

  Ranade, A A ^a,b,c,d   Joshi, D A ^a,b,c,d   Phadke, G K ^a,b,c,d   Patil, P P ^a,b,c,d   Kasbekar, R B ^e   Apte, T G ^c   Dasare, R R ^b   Mengde, S D ^f   Parikh, P M ^g   Bhattacharyya, G S ^h   Lopes, G L ⁱ  

^a Deenananth Mangeshkar Hospital   (India)

^b Clinic of General and Restorative Dentistry and Dental Implantology   (India)

^c Erandwana Gaothan   (India)

^d Oyster and Pearl Hospital ^*  (India)

^e JEHANGIR HOSPITAL   (India)

^f Avinash Cancer Clinic   (India)

^g TATA MEMORIAL HOSPITAL   (India)

^h FORTIS HOSPITAL   (India)

ⁱ Johns Hopkins Singapore   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

NANOPARTICLE; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; ANEMIA; ANGINA PECTORIS; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; CARCINOMATOUS MENINGITIS; CONTROLLED STUDY; CONVULSION; COST CONTROL; COUGHING; DEEP VEIN THROMBOSIS; DEHYDRATION; DRUG DOSAGE FORM COMPARISON; DRUG ERUPTION; DRUG FEVER; DRUG FORMULATION; DRUG USE; DYSPHAGIA; DYSPNEA; ERYTHEMA; ESOPHAGUS TUMOR; FEMALE; FOOT EDEMA; GASTROINTESTINAL SYMPTOM; HEMATEMESIS; HERPES ZOSTER; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOPROTEINEMIA; INDIA; INFUSION RELATED REACTION; INJECTION SITE EDEMA; INJECTION SITE REACTION; INTESTINE OBSTRUCTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL PRACTICE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PAIN; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RETROSPECTIVE STUDY; SOLID TUMOR; STOMACH CANCER; STOMACH TUMOR; THROMBOCYTOPENIA; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; UTERINE CERVIX CARCINOMA; VASCULAR DISEASE; VOMITING; WEAKNESS; ADVERSE DRUG REACTION; AGED; CLASSIFICATION; COST BENEFIT ANALYSIS; ECONOMICS; KAPLAN MEIER METHOD; MIDDLE AGED; NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INDIA; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NANOPARTICLES; NEOPLASMS; PACLITAXEL; TREATMENT OUTCOME;

EID: 84882995126     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt322     Document Type: Article

References (11)

1. Kulkarni NJ. India has one of the highest cancer rates in the world. http://nitawriter.wordpress.com/2007/04/26/india-has-one-of-the-highest-cancerrates-in-the-world/ (15 January 2010, date last accessed).
2. Horwitz SB. Mechanism of action of taxol. Trends Pharmacol Sci 1992; 13(4): 134-136.
3. Spencer CM, Faulds D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994; 48(5): 794-847.
4. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995; 332(15): 1004-1014.
5. Hennenfent KL, Govindan R. Novel formulations of taxanes: a review. Old wine in a new bottle? Ann Oncol 2006; 17: 735-749.
6. Wiernik PH, Schwartz EL, Strauman JJ et al. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987; 47: 2486-2493.
7. Taxol (paclitaxel) Injection [package insert]. Princeton, NJ: Bristol-Myers Squibb Company 2003.
8. Weiss RB, Donehower RC, Wiernik PH et al. Hypersensitivity reactions from taxol. JClinOncol 1990; 8(0): 1263-1268.
9. Singh AT, Jaggi M, Khattar D et al. A novel nanopolymer based tumor targeted delivery system for paclitaxel [abstract]. J Clin Oncol 2008; 26(15S): 11095.
10. Oken MM, Creech RH, Tormey DC et al. Toxicity and responses criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5(6): 649-655.
11. Ranade AA, Bapsy PP, Nag S et al. A novel, cremophor-free, polymeric nanoparticle paclitaxel (do/ndr/02) multicenter study in advanced/ metastatic breast cancer [abstract]. J Clin Oncol 2008; 26(20S): 1115.